
The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.
Karen L. Reckamp, MD, discusses a phase II, single-arm study of cabozantinib plus erlotinib for the treatment of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC).
Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, discusses a phase II, single-arm study of cabozantinib plus erlotinib for the treatment of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC).
Learn more about the combination of cabozantinib and erlotinib for NSCLC > >
over 12 years ago
Update on Next-Generation Therapies for NSCLCover 12 years ago
Adverse Events Associated With CO-1686over 12 years ago
<em>RICTOR</em> Amplification in Lung Cancerover 12 years ago
Peer Discussion on Maintenance Therapy in NSCLCover 12 years ago
Trials of Anti-PD-L1 in NSCLC Are Well Under Way




